Chinese PCSK9 Inhibitor Trial Tests IBI306 for High-Risk Cholesterol Patients
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
Summary
IBI306 is a fully human monoclonal antibody designed to block PCSK9, a protein that degrades LDL receptors on liver cells. By inhibiting PCSK9, IBI306 allows more LDL receptors to remain active, pulling more LDL cholesterol out of the bloodstream. This completed Phase 3 trial tested two dosing regimens — 450mg every four weeks and 600mg every six weeks — against placebo in Chinese adults with non-familial hypercholesterolemia who were already taking statins, with or without ezetimibe. Participants carried very high or high cardiovascular risk. The trial aimed to confirm whether IBI306 could meaningfully lower LDL-C on top of existing lipid-lowering therapy and assess its safety profile in a Chinese population, where PCSK9 inhibitor access has historically been limited.
Detailed Summary
Cardiovascular disease remains the leading cause of death globally, and elevated LDL cholesterol is one of its most modifiable risk factors. While statins are the cornerstone of lipid-lowering therapy, many high-risk patients fail to reach target LDL levels on statins alone. PCSK9 inhibitors represent a powerful next-line option, but their availability and clinical validation in Chinese populations has lagged behind Western markets.
This completed Phase 3 trial, sponsored by Innovent Biologics, investigated IBI306 — a fully human anti-PCSK9 monoclonal antibody — in Chinese adults with non-familial hypercholesterolemia and high or very high cardiovascular risk. Participants were already on background statin therapy, with or without ezetimibe, mirroring real-world clinical practice. Two active dosing arms were tested: 450mg subcutaneously every four weeks and 600mg every six weeks, both compared against placebo.
The primary mechanism of IBI306 involves binding to circulating PCSK9 and preventing it from degrading LDL receptors on hepatocytes. This restores receptor recycling, increases LDL uptake from the bloodstream, and lowers LDL-C levels. Similar agents — evolocumab and alirocumab — have demonstrated LDL reductions of 50–60% in other populations, and IBI306 was designed to replicate this efficacy in a domestically manufactured, potentially more accessible format for Chinese patients.
The trial's completion signals that efficacy and safety data have been collected, though full results have not been published in the available abstract. If results align with the drug class benchmarks, IBI306 could expand access to PCSK9 inhibition in China's large at-risk population and support regulatory approval.
Key caveats include the restriction of this summary to abstract-level data, the absence of published outcomes, and the focus exclusively on a Chinese cohort, which may limit generalizability. The non-familial hypercholesterolemia-only enrollment also means findings may not extend to FH patients.
Key Findings
- IBI306 tested at two dosing regimens — 450mg Q4W and 600mg Q6W — against placebo in statin-treated Chinese patients.
- Trial targeted adults with non-familial hypercholesterolemia and high or very high cardiovascular risk.
- Mechanism: PCSK9 blockade restores LDL receptor recycling, reducing circulating LDL-C on top of statin therapy.
- Phase 3 status is completed, suggesting full efficacy and safety results are forthcoming or under regulatory review.
- Domestic Chinese PCSK9 inhibitor development could meaningfully improve access in a high-burden cardiovascular population.
Methodology
Phase 3 randomized controlled trial with three arms: IBI306 450mg SC Q4W, IBI306 600mg SC Q6W, and placebo, enrolling Chinese adults with non-familial hypercholesterolemia on background statin therapy with or without ezetimibe. Participants had high or very high cardiovascular risk. The trial is now completed per ClinicalTrials.gov.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full study data are not publicly available. No efficacy or safety outcomes data are reported here, limiting conclusions about actual LDL reduction magnitude or adverse event rates. The trial enrolled only Chinese subjects with non-familial hypercholesterolemia, restricting generalizability to other ethnicities or familial hypercholesterolemia patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.